Baxiva is a biotechnology company developing advanced glycoconjugate vaccines to prevent bacterial infections. Their platform focuses on creating novel immunotherapies targeting pathogens with high clinical impact and increasing antimicrobial resistance, with a lead program aimed at preventing Escherichia coli infections.
Funding
Funding not disclosed
Founders
Product
Problem
Antimicrobial resistance is a growing global health crisis, with bacterial infections posing a significant clinical burden. Current vaccine development struggles to keep pace with the emergence of resistant pathogens, leaving critical unmet needs in infection prevention.
Solution
Baxiva is a biotechnology company developing advanced glycoconjugate vaccines to address these urgent global health challenges. The company's platform focuses on creating novel immunotherapies targeting pathogens characterized by high clinical impact and increasing resistance to existing treatments. Baxiva's lead program is specifically designed to prevent infections caused by Escherichia coli, a primary driver of antibiotic-resistant infections globally. This approach aims to provide a new layer of defense against debilitating and potentially life-threatening bacterial diseases.
Target Audience
Baxiva targets pharmaceutical companies and public health organizations seeking innovative solutions for infectious disease prevention, particularly those focused on combating antimicrobial resistance.
Features
- Development of next-generation glycoconjugate vaccine technology.
- Focus on pathogens with high clinical burden and rising antimicrobial resistance.
- Lead program targeting Escherichia coli infections, including urinary tract and invasive strains.
- Proprietary platform for the design and synthesis of complex carbohydrate antigens.
- Emphasis on eliciting robust and protective immune responses against bacterial pathogens.